Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00228540 · ClinicalTrials.gov registry record · Phase 3

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

A Phase 3 study of ADHD, sponsored by Cephalon.

Completed
Registry status
Phase 3
Development phase
20
Study locations

NCT00228540 is a Phase 3 study of ADHD that has completed, run by Cephalon. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00228540, a Phase 3 study of ADHD, has completed, sponsored by Cephalon.

COMPLETED
Registry status
Phase 3
Development phase
20
Study locations

Study Summary

An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)

Conditions Studied

Interventions

  • DRUG Modafinil

Study Locations (20)

Florida

  • Sarkis Clinical Trials - Gainesville
  • Clinical Neuroscience Solution - Jacksonville
  • Clinical Neurosciences - Orlando
  • Laszlo J. Mate, MD, PA - West Palm Beach

California

  • UCI Child Development Center - Irvine
  • Pharmacology Research Institut - Northridge
  • Pacific Sleep Medicine Service - San Diego

Georgia

  • Northwest Behavioral Research - Marietta
  • Pediatrics and Adolescent - Woodstock

Illinois

  • Loyola University Medical Center Department of Psychiatry - Maywood
  • HALP Clinic and ADHD Research - Northbrook

Kentucky

  • Michael J. Rieser, MD - Lexington
  • Pedia Research, LLC - Owensboro

Louisiana

  • Louisiana Research Associates - New Orleans
  • Psycopharmacology Research - LSU Health Science Center - Shreveport

Michigan

  • Odyssey Research - Dearborn
  • Hurley Medical Center - Flint

Arizona

  • Melmed Center - Scottsdale

Trial Details

FieldValue
Start Date 2005-09
Est. Completion 2006-09
Phase Phase 3

Sponsor

Cephalon

64 total trials

What the Registry Record Tells You About NCT00228540

The ClinicalTrials.gov registry entry for NCT00228540 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.

NCT00228540 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00228540 about?

NCT00228540 is a clinical study titled "Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD". An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)

What is the current status of trial NCT00228540?

This trial is currently completed. It is a Phase 3 study. The study started on 2005-09. Estimated completion is 2006-09.

What conditions does trial NCT00228540 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT00228540?

The interventions under investigation include: Modafinil (DRUG).

Who is sponsoring clinical trial NCT00228540?

This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00228540 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.